Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023445 · ClinicalTrials.gov registry record
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 37,688
- Enrollment target
NCT07023445 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37,688 participants.
The verdict
NCT07023445 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 37,688 participants
- Enrollment target
Study Summary
This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States. The study used data extracted from three databases: (1) open and closed claims from Komodo's Healthcare map and electronic medical records (EMRs) from outpatient clinics affiliated with (2) Healix and (3) Metro Infusion Centers. The study period spanned from 01 January 2021 to the latest date of the available data for each database. Index date was defined as the date of the first claim for inclisiran, alirocumab, or evolocumab within the patient identification period. The 12-month period prior to the index date (including the index date) was the baseline period. Follow-up spanned from the index date up to patient disenrollment, death, or the end of the study period, whichever came first.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,688 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2024-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023445
The ClinicalTrials.gov registry entry for NCT07023445 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37,688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07023445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07023445 about?
NCT07023445 is a clinical study titled "Patterns of Inclisiran Use in the Real World: An Analysis of US Databases". This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States. The study used data extracted from three databases: (1) open and closed claims from Komodo's Healthcare map and electronic medical records...
What is the current status of trial NCT07023445?
This trial is currently completed. The enrollment target is 37,688 participants. The study started on 2023-01-20. Estimated completion is 2024-06-28.
Who is sponsoring clinical trial NCT07023445?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.